A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Hepatocellular Carcinoma
Latest Information Update: 22 Feb 2023
At a glance
- Drugs Catequentinib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 21 Jan 2023 Results (at data cutoff: Aug 2022, n=119) assessing efficacy and safety of anlotinib plus PD-1 inhibitors in the treatment of HCC, presented at the 2023 Gastrointestinal Cancers Symposium.
- 13 Jul 2021 New trial record